New drug crovalimab aims to control rare blood disorder PNH
NCT ID NCT04654468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests crovalimab in about 50 people with PNH who have not used similar drugs before. PNH causes red blood cells to break apart, leading to fatigue, pain, and need for transfusions. Crovalimab is given as an IV infusion and then as injections under the skin to block part of the immune system and prevent red blood cell destruction. The study measures how well the drug controls hemolysis and reduces transfusion needs over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Crovalimab (a drug given by IV and injection under the skin)
- What this could lead to
- If successful, crovalimab could offer a new treatment option to control PNH, reducing red blood cell destruction and the need for blood transfusions.
- What could go wrong
- This is a single-arm, open-label trial with only 51 participants, so results may not apply broadly. Risks include infections and breakthrough hemolysis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong General Hospital
Guangzhou, 510115, China
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, 300020, China
-
Tianjin Medical University General Hospital
Tianjin, 300052, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could replace infusions for a rare blood disease?
- Every-8-Week shot could simplify PNH treatment
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients
- No treatment, just observation: large study looks at PNH blood cells
- New hope for rare blood disorder: Long-Term study of XH-S003 underway